Wearable Injectors Market Size, Share and Global Trend By Type (On-Body Wearable Injectors, Off-Body Wearable Injectors), By Application (Oncology, Neurology, Diabetes, Cardiology, Others), By End User (Hospitals, Clinics, Ambulatory Surgery Centers, Home Care Settings, Others)and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Wearable injectors are delivery systems that adhere to the body to administer drug through subcutaneous route for an extended period of time. The technology in wearable injectors offers better precision in drug delivery followed by accurate dosing, and other clinical features. All wearable injectors consists of a reservoir for medication, a cannula for delivery through the tissue, an adhesive to fix the device to patient’s skin and a drive system to deliver the appropriate volume of drug.
According to the World Health Organization,chronic disease accounted for almost 60% of the global disease and is expected to rise for about 73% in 2020. This increasing prevalence of chronic diseases is projected to drive the demand for treatment of chronic disease using wearable injectors. The cost of per unit of wearable injectors on an average is between US $20 and US $30 whereas, the cost to administer a single dose of drug via I.
To gain extensive insights into the market, Request for Customization
V infusion in hospital and clinics is between US $1000 to US $10,000. Thus wearable injectors are cost effective route of administration as compare to conventional injecting practices. Certain benefits offered by wearable injectors over conventional injections are superior drug dose and time management, improved patient comfort and convenience, and reduction in procedural errors are anticipated to drive the wearable injectors market growth. However unfavourable reimbursement policies for the xpected to restrain the growth of the global wearable injectors market during forecast period.
Key Players Covered
The major companies in the global wearable injectors market report include Consort Medical plc, Sensile Medical AG, Enable Injections, BD, Ypsomed AG, Valeritas, Inc., United Therapeutics Corporation, Medtronic, Amgen Inc. and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Type | · On-Body Wearable Injectors · Off-Body Wearable Injectors |
By Application | · Oncology · Neurology · Diabetes · Cardiology · Others |
By End User | · Hospitals · Clinics · Ambulatory Surgery Centers · Home Care Settings · Others |
By Geography | · North America (USA, Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico, Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
Key Insights
- Pricing analysis, key players 2018
- Prevalence of Chronic Diseases, Key Countries 2018
- Technological Advancements in Wearable Injectors
- Key Mergers and Acquisitions.
Regional Analysis
The global wearable injectors market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is expected to dominate the global wearable injectors market during the forecast period owing to early adoption of new healthcare technologies and growing prevalence of chronic diseases such as cancer, diabetes and others followed by rising emphasis on reduction in treatment cost and preference for patient convenience. Europe offers a high potential for the global wearable injectors market growth due to, gradual shift of patients towards self-administration. Asia Pacific and Middle East Africa are anticipated to register marginally slow growth rate as compared to other regions due to slower technology adoption in the region followed by lack of awareness in remote areas. Latin America accounts for a comparatively smaller share of global wearable injectors market during the forecast period.
Wearable Injectors Industry Developments
- In May 2019, Teva Pharmaceuticals launched its drug product Copaxone in the pre-filled autoinjector YpsoMate from Ypsomed AG to be used in treatment of patients with relapsing forms of multiple sclerosis (MS).
- In 2018, BD launched Libertas a wearable injector capable to deliver large-volume and high viscosity drugs subcutaneously.
- In November 2017, West Pharmaceutical Services announced the new extension of the SmartDose drug delivery platform that included several new wearable injectors that allowed for up to 10 mL of volume to be injected easily in patients.
- Ongoing
- 2023
- 2019-2022
Personalize this Research
- Granular Research on Specified Regions or Segments
- Companies Profiled based on User Requirement
- Broader Insights Pertaining to a Specific Segment or Region
- Breaking Down Competitive Landscape as per Your Requirement
- Other Specific Requirement on Customization
Healthcare Clients
